is...Long
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Excellent post, thanks for all your hard work.
#dcvax #allsolidtumors $nwbo #gbm https://t.co/Ou0LPoQ7Yq
— Peter Davis (@peter_brit) January 15, 2024
#dcvax #allsolidtumors $nwbo #gbm
— Peter Davis (@peter_brit) January 15, 2024
Immorta Bio@ImmortaBio
"That is so interesting to think of the synergy with other approaches such as $nwbo dendritic cells"
A great paper from Caliguri’s group showing innate lymphoid cells type 2 can kill #Cancer https://t.co/6mRIF5oY5I……
#dcvax #allsolidtumors $nwbo #gbm
— Peter Davis (@peter_brit) January 15, 2024
Immorta Bio@ImmortaBio
"Coated #exosomes for treatment of #colitis Same technology could be used to coated $nwbo dendritic cell exosomes…oral cancer immunotherapy" ? https://t.co/eNHiszlalx https://t.co/UWP2S9W7jy
#dcvax #allsolidtumors $nwbo #gbm
— Peter Davis (@peter_brit) January 15, 2024
"It is hoped that the widespread uptake of biomarker-informed precision oncology into routine clinical practice will ultimately improve outcomes for those living with cancer" https://t.co/E9Qpo83zpt
#dcvax #allsolidtumors $nwbo #gbm pic.twitter.com/cbMwurVFou
— Peter Davis (@peter_brit) January 15, 2024
#dcvax #allsolidtumors $nwbo #gbm
— Peter Davis (@peter_brit) January 15, 2024
Immorta Bio@ImmortaBio
"The dendritic cell activating molecule tlr9 is needed for B cell tolerance. Could dendritic cells be used to cure B cell autoimmune diseases such as #lupus? Truly $nwbo is sitting on a goldmine" https://t.co/CtNifvLQL1
For sure, a well positive indication and also confirmation of important work by UK Regulators to facilitate/expedite DCVax.
#dcvax #allsolidtumors $nwbo #gbm https://t.co/oDtSL5gfFk pic.twitter.com/FkPBR1Nt7i
— Peter Davis (@peter_brit) January 14, 2024
#dcvax #allsolidtumors $nwbo #gbm
— Peter Davis (@peter_brit) January 14, 2024
“The world is waiting for the next big thing — innovations that will help confront the tremendous burden of disease for patients. Addressing those diseases requires the kind of world-class, scientific exploration that we are pursuing.”
Rob… https://t.co/ZRMa7bXUPO pic.twitter.com/pCgAjj5vSa
"Incredible…cancer reprograms neutrophils for angiogenic support.@exosome
— Peter Davis (@peter_brit) January 14, 2024
this was predicted in your Immunological Control Book"
"$nwbo DC block this"https://t.co/mFxI7Typm1 https://t.co/6kUDH7nC1w pic.twitter.com/ritthsohqp
#dcvax #allsolidtumors $nwbo #gbm
— Peter Davis (@peter_brit) January 13, 2024
Merck is eyeing new immunology deals
Merck is eyeing new immunology deals, chief medical officer says: Merck wants to beef up its immunology pipeline through additional deals, the Big Pharma’s chief medical officer Eliav Barr said at an… pic.twitter.com/QPdhKhbi4S
You see that is exactly what I am talking about. I post highlighting your B/S backed with evidence, you cannot refute my evidence so you resort to a personal attack. Speaks volumes. Get a grip!
#dcvax #allsolidtumors $nwbo #gbm
— Peter Davis (@peter_brit) January 13, 2024
"While future work is needed to progress the model’s training, this project provides an example of how health data can be used to predict tumor responses to cancer vaccine immunotherapies"
The role of digital twins in personalized medicine… pic.twitter.com/b9XBzh160r
#dcvax #allsolidtumors $nwbo #gbm
— Peter Davis (@peter_brit) January 13, 2024
Advent still expanding workforce:https://t.co/Xl1tqcM8ep pic.twitter.com/tQPKFpte55
#dcvax #allsolidtumors $nwbo #gbm
— Peter Davis (@peter_brit) January 13, 2024
Approval Pathways Differ for Cancer Drugs Approved as Single Agents and Those Approved in Combination
Andrea S. Blevins Primeau, PhD, MBA | January 1
Cancer drugs approved as single agents are more likely to receive accelerated approval and to…
#dcvax #allsolidtumors $nwbo #gbm https://t.co/VnU9q4FGPt pic.twitter.com/uU9qhZRUMs
— Peter Davis (@peter_brit) January 13, 2024
#dcvax #allsolidtumors $nwbo #gbm
— Peter Davis (@peter_brit) January 13, 2024
Glioblastoma tumor cells mimic neurons to evade treatment
Jan 11 2024
"Proteomics give us a much more direct prediction of protein activity," Iavarone said. "We hope this analysis can be seamlessly translated into the clinic as a…
#dcvax #allsolidtumors $nwbo #gbm https://t.co/c5y0fK1Aex
— Peter Davis (@peter_brit) January 13, 2024
#dcvax #allsolidtumors $nwbo #gbm https://t.co/Uq4SrgqrHt
— Peter Davis (@peter_brit) January 13, 2024
#dcvax #allsolidtumors $nwbo #gbm https://t.co/25xOX0pXJY
— Peter Davis (@peter_brit) January 13, 2024
Imagine A World Where Advanced Cancers Are Not A Death Sentence #biology #DCVaxL #CancerVaccine #Immunotherapies #Immunotherapy $NWBO #GBM
— Eco Biata (@EcoBiata) January 12, 2024
Personalized combination immunotherapies to treat a dynamic immune response is the future.https://t.co/XQy1rNshce via @YouTube
Looking at the criteria #nwbo had to pass before being designated 'Promising Innovative Medicine' and allowed to treat patients with DCVax®-L under the compassionate use scheme (for the last 4+ years)
It is understandable that the statement applies.
#dcvax #allsolidtumors $nwbo #gbm
— Peter Davis (@peter_brit) January 12, 2024
"Being awarded a PIM designation and going through EAMS is a positive initial step in gaining market access. This process highlights the severity and unmet need of the disease, looking into the therapeutic benefit provided to patients which is…
Same as EX, your attempts at FUD are just a joke, sloppy and incorrect B/S (as usual)
Get a grip!
https://assets.publishing.service.gov.uk/media/5a75116f40f0b6397f35d6bb/PIM_designation_guidance.pdf
"Being awarded a PIM designation and going through EAMS is a positive initial step in gaining market access. This process highlights the severity and unmet need of the disease, looking into the therapeutic benefit provided to patients which is a strong basis for recommendation through the NICE appraisal"
#dcvax #allsolidtumors $nwbo #gbm $dcvax being the first to be designated 'Promising Innovative medicine' in the UK and being granted 'Orphan' status for the treatment of #gbm with DCVax®-L in both the US and EU comes with with very useful benefits to assist #nwbo with it's… pic.twitter.com/GV3eoYseEm
— Peter Davis (@peter_brit) January 12, 2024
#dcvax #allsolidtumors $nwbo #gbm
— Peter Davis (@peter_brit) January 12, 2024
Insights for precision oncology from the integration of genomic and clinical data of 13,880 tumors from the 100,000 Genomes Cancer Programme
Published: 11 January 2024
"For instance, in glioblastoma multiforme, small variants were present in… https://t.co/rwfZfYHlMA pic.twitter.com/4boM94c3yd
#dcvax #allsolidtumors $nwbo #gbm
— Peter Davis (@peter_brit) January 12, 2024
Infographic: Milestones in the FDA’s Real-World Evidence activities
The passing of the 21st Century Cures Act of 2016 marked a seachange within the FDA, spurring the agency to develop a number of initiatives advancing the role and use of… pic.twitter.com/VV2RuAQmY5
#dcvax #allsolidtumors $nwbo #gbm
— Peter Davis (@peter_brit) January 12, 2024
Al Musella video: 'Navigating Brain Cancer'
01/11/2024
Al's Comment:In this webinar, I, Al Musella, DPM, explore potential approaches I would consider if diagnosed with Glioblastoma. We entertain a hypothetical scenario where we have the…
#dcvax #allsolidtumors $nwbo #gbm
— Peter Davis (@peter_brit) January 12, 2024
RWE AND HTA - a snapshot of recent developments..
"it is notable that the FDA also highlight their position that trials can also generate RWE as well (for example, a single arm-trial compared with a RWD external control is classed by them as…
You also make some very good points. As I said previously I am 'open minded' and can see a number of possibilities in terms of approval dates, yours is certainly a realistic assumption. As I have previously also said, my best guess is March but I am prepared for it to take longer. Regardless of when, we are in the final stages of a very important milestone for the company which wiithout doubt it will serve as the beginning of a new era in the company's history and I am extremely confident of MHRA approval, this is the important takeaway IMO and not the time it takes to get there despite the frustration this causes.
I personally have an 'open mind' about the timing of approval. All any of us can do is speculate however, I ask myself, Is Professor Ashkan with all his many, many years of interactions with MHRA so out of touch that he recently stated, when questioned on approval, that "hopefully we will find out in a few months" (paraphrasing) ? Also, in the aftermath of Covid, it came to light that the UK Gov't didn't just exert influence over Regulatory matters in approving the vaccines, rather the health Secretary took control over the decisions. IF the Gov't see it as urgent enough and/or it meets their agenda, it will happen faster. Anything is possible however and as far as I am concerned it will take as long as it takes, I am not going anywhere
Thanks, also of note Charles River have four speakers in attendance and INmune Bio also has a speaker.
https://advancedtherapiesweek.phacilitate.com/advanced-therapies-week-speakers/
The MHRA is a UK Government agency. IMO we cannot rule out the influence that Government can perhaps bring to the speed of approving certain drugs, in particluarly drugs for an urgent unmet need, rare orphan designated condition in the UK (gbm is exactly recognised as such)
With regards to having 'swift approval' the UK Health secretary clearly stated the Government's wishes in his spring 2023 budget statement:-
Spring Budget 2023 speech
Spring Budget 2023 speech as delivered by Chancellor Jeremy Hunt.[color=red][/color]
"We are lucky with the MHRA to have one of the most respected drugs regulators in the world, indeed the very first to licence a Covid vaccine.
From 2024, they will move to a different model which will allow rapid, often near automatic sign-off for medicines and technologies already approved by trusted regulators in other parts of the world such as the United States, Europe or Japan.
At the same time from next year they will set up a[color=red] swift new approval process for the most cutting-edge medicines [/color]and devices to ensure the UK becomes a global centre for their development.
And with an extra £10m of funding over the next two years they will put in place the quickest, simplest, regulatory approval in the world for companies seeking rapid market access".
https://www.gov.uk/government/speeches/spring-budget-2023-speech#:~:text=From%202024%2C%20they%20will%20move,United%20States%2C%20Europe%20or%20Japan.
Sad reflection of greed, corruption and utter disdain of the preservation of human life, a sign of the times ?
"So, the patents really are process patents and we could file one that tweaks things a little bit, and that’s essentially that’s what Northwest Bio did. They filed multiple patents just on little tweaks of the cocktails that are used to make the cells"
#dcvax #allsolidtumors $nwbo #gbm
— Peter Davis (@peter_brit) January 8, 2024
"So, the patents really are process patents and we could file one that tweaks things a little bit, and that’s essentially that’s what Northwest Bio did. They filed multiple patents just on little tweaks of the cocktails that are used to make… https://t.co/y1ciR7o7mC
“Patents. Patents. Patents.” up there w @BIO99_BIO99 ‘s “Manufacturing. Manufacturing. Manufacturing.” $nwbo
— annie post (@apwriter) January 8, 2024
Merck's official confirmation of intention to acquire Harpoon Therapeutics.
"We also continue to strengthen our portfolio through strategic acquisitions and are prioritizing the development of several promising oncology candidates with the potential to improve the treatment of advanced cancers"
https://merck.com/news/merck-to-acquire-harpoon-therapeutics-further-diversifying-oncology-pipeline/
#dcvax #allsolidtumors $nwbo #gbm
— Peter Davis (@peter_brit) January 8, 2024
Merck's official confirmation of intention to acquire Harpoon Therapeutics.
"We also continue to strengthen our portfolio through strategic acquisitions and are prioritizing the development of several promising oncology candidates with the…
Thanks eagle, so many positive things about to hit, exciting times ahead for sure. Interesting that the results from both of the trials (keytruda combo and poly-iclc combo) are 6 months of each other.
https://clinicaltrials.gov/study/NCT04201873
https://clinicaltrials.gov/study/NCT01204684